Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Apr;65(4):471-7.
doi: 10.1136/ard.2005.040196. Epub 2005 Aug 11.

Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis

A Kavanaugh  1 , C Antoni, G G Krueger, S Yan, M Bala, L T Dooley, A Beutler, C Guzzo, D Gladman
Affiliations
Clinical Trial

Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis

A Kavanaugh et al. Ann Rheum Dis. 2006 Apr.

Abstract

Objectives: To evaluate the effect of infliximab on health related quality of life (HRQoL) and physical function in patients with active psoriatic arthritis (PsA) in the IMPACT 2 trial.

Methods: 200 patients with PsA unresponsive to conventional treatment were randomised to intravenous infusions of infliximab 5 mg/kg or placebo at weeks 0, 2, 6, 14, and 22; patients with inadequate response entered early escape at week 16. HRQoL was assessed using the Short Form-36 (SF-36) at weeks 0, 14, and 24. Functional disability was assessed using the Health Assessment Questionnaire (HAQ) at every visit through week 24. Associations between changes in quality of life (SF-36) and articular (American College of Rheumatology (ACR)) and dermatological (Psoriasis Area and Severity Index (PASI)) responses were examined.

Results: Mean percentage improvement from baseline in HAQ was 48.6% in the infliximab group compared with worsening of 18.4% in the placebo group at week 14 (p < 0.001). Furthermore, 58.6% and 19.4% of infliximab and placebo treated patients, respectively, achieved a clinically meaningful improvement in HAQ (that is, > or = 0.3 unit decrease) at week 14 (p < 0.001). Increases in physical and mental component summary (PCS and MCS) scores and all eight scales of the SF-36 in the infliximab group were greater than those in the placebo group at week 14 (p < or = 0.001). These benefits were sustained through week 24. Patients achieving ACR20 and PASI75 responses had the greatest improvements in PCS and MCS scores.

Conclusions: In patients with PsA, infliximab 5 mg/kg significantly improved HRQoL and physical function compared with placebo through 24 weeks.

PubMed Disclaimer

References

    1. Gladman D D, Shuckett R, Russell M L, Thorne J C, Schachter R K. Psoriatic arthritis (PSA)—An analysis of 220 patients. Q J Med 198762127–141. - PubMed
    1. Torre Alonso J C, Rodriguez Perez A, Arribas Castrillo J M, Ballina Garcia J, Riestra Noriega J L, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunologic and radiological study of 180 patients. Br J Rheumatol 199130245–250. - PubMed
    1. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003421460–1468. - PubMed
    1. Rahman P, Nguyen E, Cheung C, Schentag C T, Gladman D D. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 2001281041–1044. - PubMed
    1. Sokoll K B, Helliwell P S. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001281842–1846. - PubMed

Publication types